Skip to content
Medical Health Aged Care

Fear, fun and the neuroscience of Halloween: expert available for comment

Neuroscience Research Australia (NeuRA) < 1 mins read

Halloween's popularity in Australia is on the rise, with some people embracing the occasion for the spooky and the scary, while others have jumped on board for the dress-ups, lollies and fun. As people finalise their preparations for the spookiest night of the year, NeuRA Senior Research Fellow, Dr Steve Kassem, is available to discuss why we love being scared out of brains. 

Dr Kassem has qualifications in neuroscience and psychology and is passionate about science communication. His knowledge is matched by his enthusiasm for how the brain works.

Dr Kassem works in NeuRA's Brain Mapping Laboratory, a specialised facility that produces detailed atlases illustrating the regions and tracts of the human brain. Dr Kassem works to map the brain, to improve our understanding of the different regions of the brain, how they look and how they interact with each other.

 

 


About us:

Neuroscience Research Australia (NeuRA) is an independent, not-for-profit research institute based in Sydney aiming to prevent, treat and cure brain and nervous system diseases, disorders and injuries through medical research. To learn more about NeuRA: www.neura.edu.au


Contact details:

Katana Smith
Senior Media & PR Advisor
[email protected] | 0452 140 477

Media

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.